Platelet-activating anti-PF4 disorders: An overview.

Area of Science:

• Immunology
• Hematology
• Thrombosis

Background:

• Platelet factor 4 (PF4) is a cationic protein targeted by immunoglobulin G (IgG) antibodies.
• PF4's structure and IgG binding promote immune complex formation on blood cells, causing activation and potential disseminated intravascular coagulation.

Purpose of the Study:

• To review anti-PF4 disorders, including their mechanisms and clinical presentations.
• To differentiate between classic HIT, autoimmune HIT (aHIT), spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia (VITT).

Main Methods:

• Literature review of anti-PF4 antibody-mediated disorders.
• Analysis of PF4 structure, antibody interactions, and resulting immune complex formation.
• Clinical characterization of distinct anti-PF4 disorders.

Main Results:

• Four anti-PF4 disorders are discussed: classic HIT, aHIT, spontaneous HIT, and VITT.
• VITT, an ultrarare complication of adenovirus vector vaccines, presents with thrombocytopenia, DIC, thrombosis (often in unusual sites), and potent heparin-independent anti-PF4 antibodies.

Conclusions:

• Anti-PF4 antibodies play a critical role in diverse thrombotic disorders.
• Understanding the specific characteristics of anti-PF4 antibodies is crucial for diagnosing and managing these conditions, particularly the emerging VITT.